Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17310034rdf:typepubmed:Citationlld:pubmed
pubmed-article:17310034lifeskim:mentionsumls-concept:C0026896lld:lifeskim
pubmed-article:17310034lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:17310034lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:17310034pubmed:issue8lld:pubmed
pubmed-article:17310034pubmed:dateCreated2007-2-20lld:pubmed
pubmed-article:17310034pubmed:abstractTextWe compared 65 anti-acetylcholine receptor (AChR)-negative myasthenia gravis (MG) patients, including 32 anti-muscle-specific tyrosine kinase (MuSK)-positive (49%) and 33 anti-MuSK-negative (seronegative) (51%) patients, with 161 anti-AChR-positive MG patients. The anti-MuSK-positive group had a higher frequency of bulbar involvement and respiratory crises. The seronegative group was in between the anti-MuSK positive and the anti-AChR positive groups, being closer to the latter, with regard to the severity of the disease. At the end of follow-up, the outcome of the anti-MuSK-positive patients was not different from that of the anti-AChR-positive patients, although their maintenance corticosteroid dose was higher. The seronegative patients had better outcome than the other two groups.lld:pubmed
pubmed-article:17310034pubmed:languageenglld:pubmed
pubmed-article:17310034pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17310034pubmed:citationSubsetAIMlld:pubmed
pubmed-article:17310034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17310034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17310034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17310034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17310034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17310034pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17310034pubmed:statusMEDLINElld:pubmed
pubmed-article:17310034pubmed:monthFeblld:pubmed
pubmed-article:17310034pubmed:issn1526-632Xlld:pubmed
pubmed-article:17310034pubmed:authorpubmed-author:VincentAAlld:pubmed
pubmed-article:17310034pubmed:authorpubmed-author:OzdemirCClld:pubmed
pubmed-article:17310034pubmed:authorpubmed-author:SerdarogluPPlld:pubmed
pubmed-article:17310034pubmed:authorpubmed-author:DeymeerFFlld:pubmed
pubmed-article:17310034pubmed:authorpubmed-author:Saruhan-Dires...lld:pubmed
pubmed-article:17310034pubmed:authorpubmed-author:YilmazVVlld:pubmed
pubmed-article:17310034pubmed:authorpubmed-author:ParmanYYlld:pubmed
pubmed-article:17310034pubmed:authorpubmed-author:Gungor-Tuncer...lld:pubmed
pubmed-article:17310034pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17310034pubmed:day20lld:pubmed
pubmed-article:17310034pubmed:volume68lld:pubmed
pubmed-article:17310034pubmed:ownerNLMlld:pubmed
pubmed-article:17310034pubmed:authorsCompleteYlld:pubmed
pubmed-article:17310034pubmed:pagination609-11lld:pubmed
pubmed-article:17310034pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:meshHeadingpubmed-meshheading:17310034...lld:pubmed
pubmed-article:17310034pubmed:year2007lld:pubmed
pubmed-article:17310034pubmed:articleTitleClinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.lld:pubmed
pubmed-article:17310034pubmed:affiliationDepartment of Neurology, Istanbul University, Istanbul Medical Faculty, Capa, 34390 Istanbul, Turkey. deymeer@tnn.netlld:pubmed
pubmed-article:17310034pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17310034pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:17310034pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17310034lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17310034lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17310034lld:pubmed